Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4648 Comments
1656 Likes
1
Rokisha
Active Reader
2 hours ago
Really wish I had read this earlier.
👍 55
Reply
2
Rateel
Loyal User
5 hours ago
As a cautious person, this still slipped by me.
👍 21
Reply
3
Phoenicia
Daily Reader
1 day ago
Could’ve acted sooner… sigh.
👍 24
Reply
4
Ravine
Loyal User
1 day ago
I don’t know what I just read, but okay.
👍 128
Reply
5
Devlyn
Returning User
2 days ago
Early trading suggests a bullish bias, but watch afternoon sessions closely.
👍 160
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.